CJC-1295 DAC Dosage Chart: 2mg Twice Weekly

CJC-1295 DAC (Drug Affinity Complex) is a long-acting synthetic GHRH analog that covalently binds to serum albumin, extending its half-life to approximately 8 days. Short-term human studies documented dose-dependent, prolonged GH and IGF-1 elevation, but did not establish a long-term community dosing regimen. Community dosing is not based on clinical trial goals. This is not medical advice.

Research-context information only. CJC-1295 DAC is a research peptide. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

Note: CJC-1295 DAC has no standardized clinical dosing protocol. The protocol below is a Community Protocol based on clinical trial data and community experience.

Quick Reference: Community Protocol

These are community-reported schedules, not interchangeable clinical prescriptions. The embedded table uses the same examples and the primary dilution below. The published human studies used weight-based doses; they did not validate these fixed-dose cycles or compare their adherence.

Cycling Details

Teichman et al. reported a 5.8-8.1-day half-life and a cumulative effect after repeated dosing. Those findings do not establish that the fixed-dose community schedules above reach steady state after 2-3 injections or within 10-14 days.

Weeks 1-2: Community protocols document a starting dose of 1-2 mg twice weekly during the first two weeks. Community protocols describe blood work at week 4 to verify IGF-1 is in the target range (upper-normal, not supraphysiological).

Dose-adjustment claims: The cited studies do not establish a universal IGF-1 cutoff for changing a community dose or schedule. A result must be interpreted against the laboratory's age-adjusted reference range and clinical context by a licensed clinician, not converted into an automatic dose instruction.

Community-reported timing: Community sources describe once- or twice-weekly schedules, sometimes on fixed days such as Monday/Thursday. Claims that evening timing, fasting, or a particular split improves results have not been established by a head-to-head trial of these community schedules.

Routes of Administration

Subcutaneous route: The Teichman and Ionescu & Frohman studies used subcutaneous administration. Community reports also describe this route, but their site, syringe, and dilution choices are not standardized clinical instructions. The example volumes below follow the stated concentration; there is no single draw volume independent of dilution.

Reconstitution Quick Reference

Math: Community reconstitution references document this ratio: 5,000 mcg / 2.5 mL = 2,000 mcg/mL. At this concentration a 2 mg dose draws to 100 units on a standard insulin syringe; a 1 mg dose to 50 units.

Community reconstitution resources describe gentle mixing and refrigerated handling. Their often-cited 28-day multidose-vial window is not evidence of CJC-1295 chemical stability for that duration. The CJC-1295 Reconstitution Guide discusses mixing examples and their assumptions.

Affiliate disclosure: vendor links in this article are affiliate links — The Peptide Catalog may earn a commission at no additional cost to the reader.

Where These Numbers Come From

CJC-1295 DAC has short-term human clinical data for GH and IGF-1 stimulation; those studies are not validation of the fixed-dose community schedules above.

Pivotal study: Teichman et al. reported two randomized, placebo-controlled, ascending-dose studies lasting 28 and 49 days in healthy adults aged 21-61. Their abstract reports dose-dependent mean GH increases of 2-10 fold for at least 6 days and mean IGF-1 increases of 1.5-3 fold for 9-11 days after a single injection. Estimated half-life was 5.8-8.1 days; repeated dosing showed a cumulative effect (Teichman et al., 2006).

Preserved pulsatility: Ionescu & Frohman assessed healthy men before and one week after a single 60 or 90 mcg/kg injection. Pulse frequency and magnitude were unaltered. Trough GH increased 7.5-fold, while mean GH and IGF-1 increased 46% and 45%, respectively; these are study findings, not expected outcomes from a community regimen (Ionescu & Frohman, 2006).

Animal studies: CJC-1295 normalized growth in GHRH knockout mice with once-daily dosing (Alba et al., 2006). This animal result does not establish a human dosing schedule.

The fixed-dose examples and cycle lengths in community sources are not the same as these weight-based research protocols. Neither study establishes a personal IGF-1 target or a long-term safety profile for those community cycles.

Ready to buy? Compare verified vendors on our best CJC-1295 DAC sources page, or browse all coupon codes for up to 50% off. (affiliate links — we earn a commission at no extra cost to you)

Stacking Protocols

The following are community-reported combinations, not combinations validated in the cited CJC-1295 trials.

Stacking notes (community reporting): Combining with another GHRH analog (sermorelin, no-DAC CJC) is generally described as redundant rather than synergistic — they share the same GHRH receptor, so a second analog adds little once one saturates the response. The documented synergy is GHRH + GHRP (e.g., ipamorelin), which acts on a different receptor. The cited studies do not validate the safety of these combinations; interpreting GH-axis bloodwork requires clinical context. Combining with exogenous GH is not described in community protocols.

Side Effects & Safety

• Injection site reactions -- most common in clinical trials (mild erythema, pain)
• Flushing/warmth -- transient, 15-30 min post-injection
• Water retention -- described in community reports; the cited studies do not establish a comparative rate versus no-DAC
• Numbness/tingling -- carpal tunnel-like symptoms at higher doses
• Joint stiffness -- GH-mediated fluid retention
• Glucose tolerance -- GH-axis effects are a reason for clinical assessment; this article does not establish an individual monitoring schedule
• Short-study safety finding -- Teichman et al. reported no serious adverse reactions in their 28- and 49-day studies of healthy adults; that does not establish long-term safety
• Unstudied populations -- findings in healthy adults do not establish safety in pregnancy or in people with conditions such as active malignancy or diabetic retinopathy

Monitoring limits: Community sources discuss IGF-1 and glucose monitoring, but the cited CJC-1295 studies do not establish a universal 250-330 ng/mL target or a 350 ng/mL dose-adjustment threshold. Age, laboratory reference intervals, medical conditions, and other treatments affect interpretation. Monitoring does not make an unapproved regimen proven safe.

mg to Units Conversion

On a standard 100-unit insulin syringe, each "unit" equals 0.01 mL (so 100 units = 1 mL). Once CJC-1295 DAC is reconstituted, the conversion from a target dose to syringe units depends on the chosen dilution.

The two reconstitution ratios most often described in community protocols are below.

Reconstitution A: 5 mg vial + 2.5 mL BAC water (2 mg/mL) — the standard dilution from the Quick Reference above.

Reconstitution B: 5 mg vial + 1 mL BAC water (5 mg/mL) — less BAC water for a lower total volume, so smaller draws and less fridge space.

These conversions reflect the dilutions documented in community reconstitution protocols. They report how the math is described, not a recommended dosing schedule.